Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II XELOXIRI plus bevacizumab first-line study in metastatic colorectal cancer
ChiCTR2000032590Phase 2Recruiting
- Sponsor
- National Center for Biotechnology
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan, oxaliplatin, capecitabine and bevacizumab in metastatic colorectal adenocarcinoma (mCRC), sponsored by National Center for Biotechnology. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 2 more. Started Apr 2020; status: recruiting.
02
Drugs
irinotecanoxaliplatincapecitabinebevacizumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2000032590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032590.